Impelneuropharma

Press Release

admin — Thu, 18 Apr 2013 21:36:03 +0000

Impel NeuroPharma completes industry’s first nose-to-brain human imaging study
View press release

Press Release

admin — Wed, 13 Jun 2012 12:00:12 +0000

Impel NeuroPharma announces commercial milestones and first-in-human use of Pressurized Olfactory Delivery (POD) technology
View press release

The Greater Seattle Brain Science Cluster

admin — Mon, 19 Mar 2012 15:40:58 +0000

The Greater Seattle Brain Science Cluster

Impel NeuroPharma Announces Commercial and Scientific Milestones in Bypassing the Blood-Brain Barrier

admin — Thu, 20 Oct 2011 10:25:44 +0000

Impel NeuroPharma today announced a set of important milestones that accelerate its progress in enabling small molecules and biologics to bypass the blood-brain barrier.

New nasal delivery method may offer faster, better pain relief

admin — Wed, 24 Aug 2011 14:15:46 +0000

Through the nose might be a better, non-invasive route to pain relief using a “pressurized olfactory device” (POD) to deliver opioid drugs, according to research outlined in the September issue of Anesthesia & Analgesia.

Impel Snags $750K Grant

admin — Fri, 24 Jun 2011 11:51:52 +0000

Seattle-based Impel Neurpharma, the developer of technology to deliver drugs to the brain, said today it has secured a two-year, $750,000 grant from the U.S. Department of Defense.

Washington Life Sciences Discovery Fund announces grants to commercialize promising technologies

admin — Thu, 17 Feb 2011 00:00:00 +0000

The Life Sciences Discovery Fund (LSDF) today announced nearly $600,000 in awards to support commercial development of technologies to improve the diagnosis and management of major health conditions.